There is a paucity of data in treating gastric cancer patients who harbor a gBRCA mutation with PARP inhibitors. The two published trials using olaparib in gastric cancer focused more on loss of ATM as a biomarker; while a randomized phase II study of paclitaxel +/- olaparib showed a ...